Reading view
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies
Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.
ABSTRACT
Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.
PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies
Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.
ABSTRACT
Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.
PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies
Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.
ABSTRACT
Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.
PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150
Selective Test-Time Compute Scaling for Click-Through Rate Prediction via Uncertainty-Triggered Feature Path Exploration
FDX1 as a predictive biomarker and therapeutic target for lymph node metastasis in gastric cancer
Clin Exp Med. 2026 May 10. doi: 10.1007/s10238-026-02160-0. Online ahead of print.
ABSTRACT
The prognostic values of cuproptosis-related genes (CRGs) in gastric cancer with lymph node metastasis (GCLM), especially in the tumor immune microenvironment (TIME), remain unclear. We analyzed the expression, mutation, immunity, drug sensitivity, and prognostic value of CRGs in GCLM using TCGA and GEO cohorts. Consensus clustering was performed to identify CRG subtypes, with differences characterized by multi-omics analysis. A CRG-based prognostic risk score and immune score were constructed for individualized assessment, and the role of CRGs was validated through in vitro and in vivo experiments. Consensus clustering revealed that CRGs were significantly enriched in biological processes related to mitosis and energy metabolism, as well as in immune-related and cancer-associated pathways. Four distinct CRG subtypes were identified, showing marked differences in expression profiles, prognosis, genetic alterations, TIME, and chemotherapeutic drug sensitivity. We developed an exploratory CRG-based prognostic risk score for preliminary individualized assessment, and the functional relevance of CRGs in GCLM was further validated through in vitro experiments. Among these, FDX1, LIAS, DLAT, MTF1, and GLS were identified as key determinants of overall survival in patients with GCLM, with FDX1 emerging as a potential independent prognostic factor. Notably, upregulation of FDX1 significantly suppressed lymph node metastasis of gastric cancer cells in a mouse popliteal lymph node metastasis model. Our data uncovers FDX1 might be a potential favorable prognostic factors in GCLM patients. These findings may improve our understanding of CRGs in GCLM and provide new in-sights for assessing prognosis and developing more effective treatment strategies.
PMID:42107026 | DOI:10.1007/s10238-026-02160-0
Characterization and regulatory mechanism evaluation of C8orf33 in hepatocellular carcinoma through multiomics profiling
Discov Oncol. 2026 Apr 11. doi: 10.1007/s12672-026-04951-z. Online ahead of print.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality. Chromosome 8 open reading frame 33 (C8orf33) has been noted as a potential oncogenic factor in several cancers, but its biological roles and regulatory mechanism in HCC microenvironment remain unknown.
METHODS: We integrated bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics (ST) to characterize the expression landscape of C8orf33. We then performed C8orf33 loss-of-function studies in HCC cell lines, including in vitro phenotypic assays and subcutaneous xenografts.
RESULTS: C8orf33 was broadly overexpressed and associated with unfavorable prognosis across multiple Cancers. In HCC, higher C8orf33 aligned with advanced stage and shorter overall survival. C8orf33 knockdown reduced proliferation and migration, impaired tumorigenic capacity, and increased apoptosis. ScRNA-seq analyses identified a malignant population of Epi3 with high C8orf33 expression. Cell-cell communication analysis suggested that C8orf33-high Epi3 state was associated with an enriched MIF-CD74/CXCR4/CD44 signaling program toward macrophage populations with M2-like features. ST analyses further confirmed the colocalization of C8orf33 with malignant features in tumor cores. In Huh7 cells, C8orf33 knockdown was accompanied by reduced mRNA and protein levels of MIF and its receptor components. Consistently, xenografts derived from C8orf33-silenced cells showed lower expression of these MIF-axis components and reduced infiltration of CD163 and CD206-positive macrophages.
CONCLUSION: These results support a tumor-promoting association of C8orf33 in HCC and suggest a potential link to macrophage-associated immunomodulatory features, nominating C8orf33 as a candidate biomarker and therapeutic target.
PMID:41965457 | DOI:10.1007/s12672-026-04951-z
Characterization and regulatory mechanism evaluation of C8orf33 in hepatocellular carcinoma through multiomics profiling
Discov Oncol. 2026 Apr 11. doi: 10.1007/s12672-026-04951-z. Online ahead of print.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality. Chromosome 8 open reading frame 33 (C8orf33) has been noted as a potential oncogenic factor in several cancers, but its biological roles and regulatory mechanism in HCC microenvironment remain unknown.
METHODS: We integrated bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics (ST) to characterize the expression landscape of C8orf33. We then performed C8orf33 loss-of-function studies in HCC cell lines, including in vitro phenotypic assays and subcutaneous xenografts.
RESULTS: C8orf33 was broadly overexpressed and associated with unfavorable prognosis across multiple Cancers. In HCC, higher C8orf33 aligned with advanced stage and shorter overall survival. C8orf33 knockdown reduced proliferation and migration, impaired tumorigenic capacity, and increased apoptosis. ScRNA-seq analyses identified a malignant population of Epi3 with high C8orf33 expression. Cell-cell communication analysis suggested that C8orf33-high Epi3 state was associated with an enriched MIF-CD74/CXCR4/CD44 signaling program toward macrophage populations with M2-like features. ST analyses further confirmed the colocalization of C8orf33 with malignant features in tumor cores. In Huh7 cells, C8orf33 knockdown was accompanied by reduced mRNA and protein levels of MIF and its receptor components. Consistently, xenografts derived from C8orf33-silenced cells showed lower expression of these MIF-axis components and reduced infiltration of CD163 and CD206-positive macrophages.
CONCLUSION: These results support a tumor-promoting association of C8orf33 in HCC and suggest a potential link to macrophage-associated immunomodulatory features, nominating C8orf33 as a candidate biomarker and therapeutic target.
PMID:41965457 | DOI:10.1007/s12672-026-04951-z
A Data-driven Approach for Biomarker Discovery based on U-centered Distance Correlation Network: Multi-omics Warning Signals for Non-small Cell Lung Cancer
Comb Chem High Throughput Screen. 2026 Mar 27. doi: 10.2174/0113862073445368260131002109. Online ahead of print.
ABSTRACT
INTRODUCTION/OBJECTIVE: Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Alterations in metabolic activities play important roles in NSCLC development, wherein related genes and metabolites interact with each other, involving multiple forms.
METHODS: To comprehensively understand the pathogenic mechanisms and improve the performance of clinical early, precise diagnosis, this study proposed a data-driven approach for biomarker discovery based on U-centered distance correlation network (DCN) to investigate NSCLC metabolism-related reactions. In DCN, changes in molecular relationships during NSCLC initiation and progression are measured using the t-statistics of U-centered distance correlation for network construction, in which prospective warning signals representing NSCLC onset can be identified without human intervention. Additionally, the network construction criterion in DCN can precisely and effectively capture both linear and nonlinear molecular relationships in simple and biologically relevant manners.
RESULTS: DCN was successfully employed to analyze NSCLC metabolism-related metabolomics and genomics datasets. Statistical analyses confirmed that compared with other algorithms, the gene and metabolite biomarker panels identified by DCN provided more reliable diagnostic capabilities for clinical NSCLC detection. Biological analyses revealed that disturbed energy metabolism and lipid metabolism occurred during tumor cell proliferation and growth in NSCLC patients.
DISCUSSION: The gene ASPA and metabolite aspartic acid were significantly decreased in NSCLC samples, suggesting that the corresponding amino acid metabolic activities were intricately linked to NSCLC progression.
CONCLUSION: These findings demonstrated that DCN can further facilitate NSCLC studies to improve clinical outcomes in patients.
PMID:41937706 | DOI:10.2174/0113862073445368260131002109
A Data-driven Approach for Biomarker Discovery based on U-centered Distance Correlation Network: Multi-omics Warning Signals for Non-small Cell Lung Cancer
Comb Chem High Throughput Screen. 2026 Mar 27. doi: 10.2174/0113862073445368260131002109. Online ahead of print.
ABSTRACT
INTRODUCTION/OBJECTIVE: Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Alterations in metabolic activities play important roles in NSCLC development, wherein related genes and metabolites interact with each other, involving multiple forms.
METHODS: To comprehensively understand the pathogenic mechanisms and improve the performance of clinical early, precise diagnosis, this study proposed a data-driven approach for biomarker discovery based on U-centered distance correlation network (DCN) to investigate NSCLC metabolism-related reactions. In DCN, changes in molecular relationships during NSCLC initiation and progression are measured using the t-statistics of U-centered distance correlation for network construction, in which prospective warning signals representing NSCLC onset can be identified without human intervention. Additionally, the network construction criterion in DCN can precisely and effectively capture both linear and nonlinear molecular relationships in simple and biologically relevant manners.
RESULTS: DCN was successfully employed to analyze NSCLC metabolism-related metabolomics and genomics datasets. Statistical analyses confirmed that compared with other algorithms, the gene and metabolite biomarker panels identified by DCN provided more reliable diagnostic capabilities for clinical NSCLC detection. Biological analyses revealed that disturbed energy metabolism and lipid metabolism occurred during tumor cell proliferation and growth in NSCLC patients.
DISCUSSION: The gene ASPA and metabolite aspartic acid were significantly decreased in NSCLC samples, suggesting that the corresponding amino acid metabolic activities were intricately linked to NSCLC progression.
CONCLUSION: These findings demonstrated that DCN can further facilitate NSCLC studies to improve clinical outcomes in patients.
PMID:41937706 | DOI:10.2174/0113862073445368260131002109
Rapid and noninvasive artificial intelligence-assisted diagnostic method for oral squamous cell carcinoma
npj Digital Medicine, Published online: 31 March 2026; doi:10.1038/s41746-026-02527-3
Rapid and noninvasive artificial intelligence-assisted diagnostic method for oral squamous cell carcinoma